

**EMERGENCY USE AUTHORIZATION (EUA)
SUMMARY Viracor SARS-CoV-2 Assay DTC
(Viracor Eurofins Clinical Diagnostics)**

For *In vitro* Diagnostic Use
For use under Emergency Use Authorization (EUA) only

(The Viracor SARS-CoV-2 Assay DTC will be performed at laboratories designated by Viracor Eurofins Clinical Diagnostics, which are also certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a and meet the requirements to perform high complexity tests, as described in the laboratory procedures reviewed by FDA under this EUA.)

INTENDED USE

The Viracor SARS-CoV-2 Assay DTC is a direct to consumer product for testing of anterior nasal swab specimens collected using the EmpowerDX COVID-19 Home Collection Kit DTC when used consistent with its authorization.

Testing of collected anterior nasal swab specimens is limited to laboratories designated by Viracor Eurofins Clinical Diagnostics, which are also certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263, and meet the requirements to perform high-complexity tests.

Results are for the identification of SARS-CoV-2 viral RNA. SARS-CoV-2 RNA is generally detectable in anterior nasal swab specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities. Negative results do not preclude SARS-CoV-2 infection.

The Viracor SARS-CoV-2 Assay DTC is not a substitute for visits to a healthcare provider. The information provided by this product should not be used to start, stop, or change any course of treatment unless advised by your healthcare provider.

The Viracor SARS-CoV-2 Assay DTC is only intended for use by qualified clinical laboratory personnel specifically instructed and trained in the techniques of real-time RT-PCR assays and *in vitro* diagnostic procedures. The assay is intended for use under the Food and Drug Administration's Emergency Use Authorization.

DEVICE DESCRIPTION AND TEST PRINCIPLE

The Viracor SARS-CoV-2 Assay DTC is a real-time reverse transcription polymerase chain reaction (rRT-PCR) test. The Viracor SARS-CoV-2 Assay DTC primer and probe sets are designed to detect RNA from SARS-CoV-2 in anterior nasal swab specimens

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

collected at home using the EmpowerDX COVID-19 Home Collection Kit DTC when used consistent with its authorization.

Nucleic acid extractions are performed using a bioMérieux NucliSENS easyMAG or eMAG instrument with bioMérieux NucliSENS nucleic acid extraction reagents. The ThermoFisher MagMax Viral/Pathogen Nucleic acid isolation kit and GSD NovaPrimer RNA extraction kit with the ThermoFisher KingFisher FLEX for automated extraction can also be used. The Viracor SARS-CoV-2 Assay DTC nucleic acid amplification assay is a real-time (TaqPath) reverse transcription polymerase chain reaction assay for the amplification and detection of SARS-CoV-2 genomic RNA. Oligonucleotide primers hybridize to specific nucleotide sequences of the SARS-CoV-2 N gene. RNA is reverse transcribed and then amplified in the presence of thermostable DNA polymerase (Taq) enzyme and deoxy nucleotide triphosphates (dNTPs). A dual-labeled oligonucleotide probe that is complementary to an internal sequence of the amplification product is also present in the RT-PCR reaction mixture. The 5' exonucleolytic activity of Taq cleaves the fluorescent molecule (FAM) at the 5' end of the dual-labeled probe, thus releasing it from the effects of a fluorescence-quenching molecule (e.g. Black Hole Quencher 1) at the 3' end of the probe.

Additionally, oligonucleotide primers and a TaqMan probe for PCR detection of an internal extraction and amplification control are also present in the SARS-CoV-2 RT-PCR reaction mix. This allows for the simultaneous detection of internal extraction/amplification control DNA in a multiplex reaction for each sample. Fluorescence intensity for both SARS-CoV-2 amplification and internal control amplification is measured in individual wells during each of the 40 amplification cycles. A sample is considered positive when the signal intensity exceeds a predetermined baseline threshold value. The cycle number at which this occurs is referred to as the cycle threshold C_T . Detection of SARS-CoV-2 RNA in a sample is determined by the C_T value.

INSTRUMENTS USED WITH TEST

The Viracor SARS-CoV-2 Assay DTC assay is to be used with the following instruments:

1. bioMérieux NUCLISENS easyMAG and bioMérieux EMAG for automated nucleic acid extraction and the Applied Biosystems 7500 Real-Time PCR Systems (SDS v1.5.1) for nucleic acid amplification and detection.
2. ThermoFisher MagMax Viral/Pathogen Nucleic acid isolation kit and GSD NovaPrime RNA Extraction with ThermoFisher KingFisher FLEX for automated nucleic acid extraction and Applied Biosystems 7500 Fast Real-Time PCR System

Designated laboratories will receive an FDA accepted instrument qualification protocol included as part of the laboratory SOP and will be directed to execute the protocol prior to testing clinical samples. Designated laboratories must follow the authorized SOP, which includes the instrument qualification protocol, as per the letter of authorization.

Table 1: Reagents and Materials For Viracor SARS-CoV-2 Assay DTC

Reagent	Manufacturer	Catalog #
TaqPath 1-step RT-qPCR master mix, CG	Life Technologies	A15299 or A15300
COV2 Assay Oligo Mix	Viracor Eurofins	25 700143
RNase Free H2O	Fisher Scientific or equivalent	BP561-1 or equivalent
MS2 RNA bacteriophage (internal control)	ATCC	15597
SARS-CoV-2 Low positive control	Viracor	25 000414
SARS-CoV-2 High Positive Control	Viracor	25 000415
Plasma Negative Extraction Control	Viracor	25 000003
COV2 Curve Control 1 (S2)	Viracor	25850048
COV2 Curve Control 2 (S4)	Viracor	25 850048

CONTROLS TO BE USED WITH THE SARS-COV-2 RT-PCR

1. A negative (no template) control is needed to eliminate the possibility of sample contamination on the assay run and is used on every assay plate. This control has no extracted nucleic acid added to the rRT-PCR reaction. This control reaction contains RNase-, DNase-free water, the oligonucleotide primers and probes for SARS-CoV-2, as well as the internal control primers and probes.
2. A positive template control is needed to verify that the assay run is performing as intended and is included in each testing run. The positive control material is cloned plasmid DNA representing the N gene of SARS-CoV-2 (GenBank accession [NC_045512.2](https://www.ncbi.nlm.nih.gov/nuccore/NC_045512.2)).
3. Two SARS-CoV-2 positive amplification curve controls (low and high) are included on each amplification plate to ensure that SARS-CoV-2 RNA can be detected by the rRT-PCR test and demonstrate that the anticipated level of sensitivity has been achieved. This control material is *in vitro* transcribed RNA.
4. An internal control is needed to verify that nucleic acid is present in every sample and is used for every sample processed. MS2 (an RNA bacteriophage) is an internal lysis, extraction and amplification control that is added to each clinical specimen as the first step of nucleic acid extraction. Oligonucleotide primers and a TaqMan probe for detection of MS2 are included in primer/probe mixtures in combination with SARS-CoV-2 primers and probes. Additionally, a primer/probe set detecting human RNaseP is included to ensure an adequate biological specimen is present in home-collected specimens.
5. A negative control is needed to monitor for any cross-contamination that occurs during the RT-PCR process. This control consists of known negative phosphate buffered saline that has previously been tested for SARS-CoV-2 by rRT-PCR. This control goes through the entire extraction and amplification process with every set of samples. The resulting eluted nucleic acid from this control is added

to the rRT-PCR reaction as the negative control well. This control reaction contains all oligonucleotide primers and probes for the SARS-CoV-2, as well as the internal control target.

INTERPRETATION OF RESULTS

The test is run as a multiplex reaction with SARS-CoV-2 N1, SARS-CoV-2 N2 and MS2 internal control assays combined in a single tube. Since both SARS-CoV-2 N1 and SARS-CoV-2 N2 assays use probes with the same fluorophore (FAM), a single SARS-CoV-2 C_T value is generated and interpreted for each rRT-PCR reaction. The MS2 fluorescence signal is differentiated from SARS-CoV-2 since different fluorophore (Cy5) is used for the MS2 probe. All test controls should be examined prior to interpretation of individual results. If the controls are not valid, the individual results cannot be interpreted, and results cannot be reported.

1) Viracor SARS-CoV-2 Assay DTC Controls – Positive, Negative, and Internal:

- Negative (no template control) – the no template control should be negative for all targets detected (C_T Not Detected)
- Positive controls – Each lot of working concentration positive control is analyzed to generate lot specific C_T acceptance ranges. A C_T value within established ranges ensures that the reproducibility and repeatability of the test is consistent between days, equipment and analysts.
- Internal control – The expected C_T value for MS2 is ≤ 35. The expected C_T value for the RNaseP control is <40. In samples with no SARS-CoV-2 target detected, a C_T value less than or equal to these values for MS2 and RNaseP RNA demonstrates that effective nucleic acid extraction and rRT-PCR amplification has been achieved.
- Negative control– this control should be negative for the SARS-CoV-2 assay but positive for the MS2 internal control

If any control does not perform as described above, the run is considered invalid and all specimens are repeated from extraction.

Table 2: Interpretation of Results For Internal, No Template, Negative and Positive Control Reactions

Control	Valid result ^a	Invalid result
Internal control (MS2)	C _T < 35	C _T > 35 ^{b, c}
No template control	No amplification signal detected	Amplification detected
RNase P control	C _T < 40	C _T > 40 ^{d, e}
Negative control	No amplification signal detected	Amplification detected

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

Positive amplification curve control (low)	C_T 23 – 27	$C_T < 23$ or > 27
Positive amplification curve control (high)	C_T 9.7 – 13.7	$C_T < 9.7$ or > 13.7
Positive control (low)	C_T 26.79 – 29.73	$C_T < 26.79$ or > 29.73
Positive control (high)	C_T 20.21 – 23.03	$C_T < 20.21$ or > 23.03

^aIndividual results can only be interpreted if all control reactions generate valid results.

^bIn clinical specimens with SARS-CoV-2 target “Not detected” (i.e. $C_T > 38$), results are invalid when internal control MS2 C_T values are > 35 .

^cIn clinical specimens with SARS-CoV-2 target “Detected” (i.e. $C_T \leq 38$), internal control MS2 C_T values are not interpreted.

^dIn clinical specimens with SARS-CoV-2 target “Not detected” (i.e. $C_T > 38$), results are invalid when RNase P control $C_T > 40$.

^eIn clinical specimens with SARS-CoV-2 target “Detected” (i.e. $C_T \leq 38$), RNase P control C_T values are not interpreted.

2) Examination and Interpretation of Individual Specimen Results:

Assessment of clinical specimen test results should be performed after the controls have been examined and determined to be valid and acceptable. When all control values are valid as stated above, results of individually tested specimens are reported as shown in the table below:

Table 3: Interpretation of Individual Results from Individually Tested Specimens

Real-time RT-PCR result	Reported result
$C_T > 38$	SARS-CoV-2 RNA “Not Detected”
$C_T \leq 38$	SARS-CoV-2 RNA “Detected”

INSPECTION OF SPECIMENS:

Specimens received at the clinical laboratory for testing with Viracor SARS-CoV-2 Assay DTC for the detection of SARS-CoV-2 RNA that is indicated for use with anterior nasal swab specimens collected with the EmpowerDX COVID-19 Home Collection Kit DTC will undergo the full accessioning by the laboratory prior to acceptance for testing, using the “Self-Collection Specimen Receipt and Accessioning SOP”.

PERFORMANCE EVALUATION

(The Viracor SARS-CoV-2 Assay DTC is the same real-time PCR test as the EUA authorized prescription use only [Viracor SARS-COV-2 Assay](#). The performance evaluation of the Viracor SARS-CoV-2 Assay DTC described below is the same data used to support the authorization of the prescription use only Viracor SARS-CoV-2

Assay -. For clarity the “Viracor SARS-CoV-2 Assay” name is maintained in the summary of the performed studies)

1) Analytical Sensitivity:

Limit of Detection (LoD):

The analytical sensitivity of Viracor SARS-CoV-2 RT-PCR test was determined in Limit of Detection (LoD) studies. Since no quantified viral isolates of SARS-CoV-2 were available for testing*, stocks of 1.5 kb *in vitro* transcribed (IVT) RNA of the SARS-CoV-2 N gene (positions 28061 – 29533 of GenBank accession NC_045512.2) were used for spiking into clinical samples negative for SARS-CoV-2. These samples included BAL, nasal wash, and nasopharyngeal swab matrices. The number of RNA copies/μL of the stock IVT RNA was determined to be 1.7×10^{12} copies/μL by Qubit Broad Range (BR) RNA reagents and associated fluorometer. To determine the preliminary LoD, range finding experiments were performed on three spiked extraction/amplification replicates using 2-fold dilutions of IVT in BAL, nasal wash and nasopharyngeal swab matrices. Samples were extracted using the bioMerieux NucliSENS easyMAG and bioMerieux eMAG for nucleic acid extraction and tested using the ABI 7500 Real-Time PCR thermocycler. Results are shown in Table 4 below:

Table 4: Summary of Limit of Detection Range Finding Results Using SARS-CoV-2 N Gene IVT

RNA concentration (copies/mL)	Bronchoalveolar lavage		Nasal wash		Nasopharyngeal swabs	
	No. pos./ No. tested	C _T mean (SD) ¹ ²	No. pos./ No. tested	C _T mean (SD) ²	No. pos./ No. tested	C _T mean (SD) ²
292	3/3	33.40 (0.42)	3/3	33.82 (0.31)	3/3	33.30 (0.58)
146	3/3	34.64 (0.41)	3/3	34.88 (0.35)	3/3	33.76 (0.33)
73	3/3	37.68 (2.75)	3/3	35.58 (0.82)	3/3	35.55 (1.19)
37	3/3	36.84 (1.39)	3/3	37.02 (0.51)	3/3	36.47 (0.52)
18	1/3	N.A. ³	2/3	N.A.	3/3	36.46 (0.84)
9	1/3	N.A.	0/3	N.A.	0/3	N.A.

¹Standard deviation

² Assay targets are detected in a single well by probes labeled with the same fluorophore, resulting in a single C_T value for each positive sample.

³Not applicable

The provisional LoD was 37 – 73 copies/mL. To confirm the final LoD, 20 extraction/amplification replicates for each sample matrix at the provisional LoD values identified in the range finding experiment were tested. These results demonstrated detection rates of $\geq 95\%$ at 73 copies/mL for each of the three sample matrices tested. The LoD for each of the three matrices, therefore, is 73 copies/mL.

The LoD (73 copies/mL) was also confirmed when nucleic acid was extracted using the ThermoFisher MagMax Viral/Pathogen Nucleic Acid Isolation kit on the ThermoFisher KingFisher FLEX instrument platform and then tested on the Applied

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

Biosystems 7500 Fast Real-Time PCR System. Additionally, the GSD Extraction kit on the ThermoFisher KingFisher FLEX instrument platform was validated via a side-by-side study comparing detection of a diluted positive clinical sample at the limit of detection with the MagMax workflow:

	# positive replicates	Mean Ct of SARS-CoV-2
MagMax Extraction	20/20	35.68
GSD Extraction	20/20	35.85

*The LoD study was conducted in March 2020 and initially published at the time of the original authorization of the prescription use only Viracor SARS-CoV-2 Assay on April 6, 2020, when SARS-CoV-2 virus isolates, or clinical samples were not widely available.

2) **FDA SARS-CoV-2 Reference Panel Testing**

The evaluation of sensitivity and MERS-CoV cross-reactivity was performed using reference material (T1), blinded samples and a standard protocol provided by the FDA. The study included a range finding study and a confirmatory study for LoD. Blinded sample testing was used to establish specificity and to confirm the LoD. Nucleic acid extraction was performed by the ThermoFisher KingFisher FLEX instrument using ThermoFisher MagMAX Viral/Pathogen Nucleic Acid Isolation kits for nucleic acid extraction. The amplification was run on the Applied Biosystems 7500 Real-Time PCR Systems (SDS v1.5.1) for nucleic acid amplification and detection. The results are summarized in the following Table.

Table 5: Summary of LoD Confirmation Result using the FDA SARS-CoV-2 Reference Panel

Reference Materials Provided by FDA	Specimen Type	Product LoD	Cross-Reactivity
SARS-CoV-2	Nasopharyngeal Swabs ¹	1.8x10 ² NDU/mL	N/A
MERS-CoV		N/A	ND

NDU/mL = RNA NAAT detectable units/mL

N/A: Not applicable; ND: Not Detected

¹ The Viracor SARS-CoV-2 Assay is authorized for use with nasopharyngeal (NP) swabs. NP swab results are viewed as representative of results for all upper respiratory swab types, including anterior nasal swabs.

3) **Analytical Inclusivity**

A total of 81,765 sequences from the GISAID database covering Viracor SARS-CoV-2 assay were aligned to the N1 and N2 assay primer and probe sequences. Alignments in which the SARS-CoV-2 sequences contained either an N or a degeneracy (e.g. R, M) were eliminated from analysis. All sequences covering only part of the full Viracor assays (N1 and N2) were also eliminated for analysis. A total of 80,478 sequences remained and were then subjected to analysis for mismatches relative to

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

Viracor SARS-CoV-2 N1 and N2 primer and probe sequences. Figure 1 summarizes the results.




Figure 1. Summary of *in silico* analysis of Viracor SARS-CoV-2 Assay for inclusivity:

Description – There were a total 80478 sequences from GISAID at the time of the analysis. Of these 80478 total sequences, 49871 had 100% match for the N1 and N2 assays, and 30607 sequences remained. Of the 30607 sequences, 29886 had 100% match for the N1 assay, and 721 sequences remained. Of the 721 sequences, 430 had 100% match for the N2 assay, and 291 sequences remained. Of the 291 sequences, 251 were sequences with a 3 base substitution 16 bases from 3' of N2_F1 (Variant 1), and 40 sequences remained. Of the 40 sequences, 7 sequences were with mismatches > 11 bases from 5' end of probe or >20 bases from the 3' end of one primer, 9 sequences were with 5 mismatches > 16 bases from 3' end of N2_F1 and 1 base substitution from 3' end of N1_F1 (Variant 2), and 24 sequences were with a single mismatch 2 bases from 5' end of N1 probe and a 1 base substitution at the 3' end of N2_F1 (Variant 3).

A total of 80,187 (99.64%) of GISAID sequences as of September 20, 2020 demonstrated 100% identity to both forward and reverse primers and the probe for at least one of the two Viracor assay primer/probe sets (N1 and N2), and it was concluded that these sequences would be effectively detected by the Viracor assay. A total of 291 sequences (0.36%) were subjected to further analysis. A total of 251 sequences (variant 1) shared a common mutation, which consists of a 3 base substitution 16 bases upstream of the 3' end of the N2 forward primer (N2_F1) and did not have 100% identity for each of the N1 assay primers and probes. To investigate the impact of the 3-base mismatch in N2_F1, a synthetic DNA molecule

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

representing this variant was synthesized (Integrated DNA Technologies) along with a separate wild-type (100% match to N2 primers and probe) DNA molecule. rRT-PCR testing was performed using both the variant and wild-type template. On average the C_T values increased 1.35 cycles with the variant template, with higher C_T shifts noted at lower template concentrations. Importantly, the lowest concentrations of template tested were at 1 – 2 x the LoD of the assay (75 copies/mL) and 4 of 4 samples tested were positive with C_T values below the cutoff ($C_T \leq 38$). Of the remaining 40 (0.05%) sequences, 7 had single mismatches more than 11 bases from the 5' end of the probe or more than 20 bases from the 3' end of one primer and these 7 sequences were not considered to significantly impact inclusivity. For variant 2, a total of 9 sequences had the same 3 base substitution as variant 1 plus an additional 2 bases at the 5' end of N2_F1. To determine the impact of this mutation, a synthetic DNA molecule with the variant 2 sequence will be compared to wild-type template. For variant 3, a total of 24 sequences had a single mismatch 2 bases from 5' end of N1_P1 probe. All of the variant 3 sequences also had a 1 base substitution at the 3' end of N2_F1 which would likely prevent the N1 assay from detecting SARS-CoV-2. To determine the impact of this N1 probe mutation, a synthetic DNA molecule with the variant 3 sequence will be compared to wild-type template.

In summary, 99.64% of sequences analyzed had 100% identity to both primers and probes of at least one of the two primer/probe sets in Viracor SARS-CoV-2 rRT-PCR assay. Experimental rRT-PCR results demonstrate that an additional 0.31% of sequences would be detected with a minor (1.35 cycle) shift in C_T values. The locations of single base mismatches strongly suggest no impact on detection for 7 sequences (0.01%) analyzed. Experiments are underway to determine the impact of mismatches identified in two variants representing 33 (0.04%) of the sequences analyzed.

In addition to the above, Viracor SARS-CoV-2 assay N1 and N2 primer and probe sequences were aligned to emerging variants of potential public health importance. The results of these analyses are summarized in the table below.

Table 6: Summary of *in silico* analysis of Viracor's SARS-CoV-2 assay (N1 and N2 primers/probes) for detection of SARS-CoV-2 variants of potential public health importance.

Variant	Lineage	No. sequences		Assay coverage for strains <100% in N1 or N2 assay
		Total Identified	100% match for N1 and/or N2 assay ¹	
UK	B.1.1.7 (N501Y.V1)	17,307	17,168 (99.1%)	3 base mismatch in N2 forward primer 16 bases from 3' end.
South Africa	B.1.351 (N501Y.V2)	400	393 (98.3%)	Single base mismatch in N2 forward primer 13 bases from 3' end.
California	B.1.429 (CAL.20C0)	360	355 (98.6%)	Single base mismatch in N2 forward primer 13 bases from 3' end.
Brazilian	P.1	11	11 (100%)	Not applicable

The *in silico* analysis predicts that these variants of potential public health importance

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

would be detected by the Viracor SARS-CoV-2 Assay. For the strains that do not have 100% identity with each primer and the probe for one of the two targets (N1 and N2) of the Viracor assay, the mismatches in the impacted target are distant from the 3' end of the primer and are not likely to lead to a significant impact on detection. For the UK variant, Viracor has demonstrated experimentally that the 3-base mismatch in N2 forward primer located 16 bases from 3' end result in a minor (1.35 cycle) shift in C_T values.

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

4) Cross reactivity

Cross-reactivity (analytical specificity) was evaluated by *in silico* analysis against normal flora, pathogens that cause similar symptoms, and pathogens related to SARS-COV-2. The pathogens evaluated by *in silico* analysis by taxon identification (taxon ID) and the accession with the highest percent identity for each primer are shown in Table 7 below:

Table 7: In Silico Analysis for Cross Reactivity

Pathogen	taxon ID		Oligonucleotide primer or Taqman probe					
			N1 forward	N1 probe	N1 reverse	N2 forward	N2 probe	N2 reverse
Human coronavirus 229E	11137	% Ident.	65.0%	51.9%	59.3%	N.A.	50.0%	56.5%
		Acc. No.	KT253264.1	KT253271.1	KT253270.1	N.A.	KT253271.1	KT253272.1
Human coronavirus OC43	31631	% Ident.	N.A.	63.0%	N.A.	N.A.	N.A.	N.A.
		Acc. No.	N.A.	AY903460.1	N.A.	N.A.	N.A.	N.A.
Human coronavirus HKU1	290028	% Ident.	N.A.	51.9%	59.3%	N.A.	N.A.	N.A.
		Acc. No.	N.A.	DQ339101.1	AY884001.1	N.A.	N.A.	N.A.
Human coronavirus NL63	277944	% Ident.	N.A.	N.A.	66.7%	N.A.	N.A.	N.A.
		Acc. No.	N.A.	N.A.	MK334045.1	N.A.	N.A.	N.A.
SARS coronavirus	694009	% Ident.	100%	59.3%	89.9%	91.7%	N.A.	95.7%
		Acc. No.	AY297028.1	KJ473811.1	KY352407.1	AY297028.q	N.A.	AY297028.1
MERS coronavirus	1335626	% Ident.	75.0%	N.A.	59.3%	N.A.	N.A.	N.A.
		Acc. No.	KJ473821.1	N.A.	MG923469.1	N.A.	N.A.	N.A.
Human adenovirus	1907210	% Ident.	70.0%	N.A.	59.3%	62.5%	72.7%	60.9%
		Acc. No.	LC215429.1	N.A.	MK570618.1	LC215429.1	KY002683.1	MK241690.1
Human metapneumovirus	162145	% Ident.	65.0%	55.6%	59.3%	N.A.	N.A.	56.5%
		Acc. No.	KJ627397.1	AY525843.1	KJ627383.1	N.A.	N.A.	AF371337.2
Parainfluenza virus 1	12730	% Ident.	70.0%	44.4%	81.5%	66.7%	N.A.	56.5%
		Acc. No.	M14887.1	AF457102.1	KF687307.1	AF457102.1	N.A.	KX639498.1
Parainfluenza virus 2	1979160	% Ident.	65.0%	N.A.	59.9%	58.3%	N.A.	60.9%
		Acc. No.	NC_003443.1	N.A.	AF533011.1	KM190939.1	N.A.	NC_003443.1
Parainfluenza virus 3	11216	% Ident.	60.0%	N.A.	66.7%	N.A.	N.A.	69.6%
		Acc. No.	KM190938.1	N.A.	KY973556.1	N.A.	N.A.	MH678682.1
Parainfluenza virus 4	1979161	% Ident.	60.0%	44.4%	66.7%	N.A.	N.A.	47.8%
		Acc. No.	NC_021928.1	MH892407.1	KY460515.1	N.A.	N.A.	KF483663.1
Influenza A virus	11320	% Ident.	65.0%	51.9%	62.9%	70.8%	63.6%	69.6%
		Acc. No.	AB827993.1	AB818499.1	NC_007367.1	HE589468.1	AB822988.1	NC_007371.1
Influenza B virus	11520	% Ident.	65.0%	59.3%	59.3%	58.3%	59.1%	60.9%
		Acc. No.	NC_002206.1	NC_002211.1	NC_002205.1	NC_002207.1	NC_002205.1	NC_002211.1
Enterovirus	12059	% Ident.	85.0%	51.8%	74.1%	N.A.	72.7%	82.6%
		Acc. No.	KP202389.1	MK593172.1	FJ445142.1	N.A.	FJ445125.1	AB647318.1
Respiratory	11250	% Ident.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

syncytial virus		Acc. No.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
Rhinovirus	433730	% Ident.	85.0%	62.9%	74.1%	75%	72.7%	65.2%
		Acc. No.	MG950178.1	DQ473499.1	FJ445142.1	FJ445174.1	FJ445125.1	FJ445147.1
<i>Chlamydia pneumoniae</i>	83558	% Ident.	N.A.	N.A.	51.9%	70.8%	68.2%	N.A.
		Acc. No.	N.A.	N.A.	CP001713.1	AE009440.1	AE009440.1	N.A.
<i>Haemophilus influenza</i>	727	% Ident.	N.A.	N.A.	74.1%	N.A.	86.4%	N.A.
		Acc. No.	N.A.	N.A.	CP031689.1	N.A.	NC_000907.1	N.A.
<i>Legionella pneumophila</i>	446	% Ident.	85.0%	N.A.	77.8%	N.A.	N.A.	N.A.
		Acc. No.	CP041668.1	N.A.	CP025491.2	N.A.	N.A.	N.A.
<i>Mycobacterium tuberculosis</i>	1773	% Ident.	N.A.	N.A.	N.A.	N.A.	81.8%	N.A.
		Acc. No.	N.A.	N.A.	N.A.	N.A.	CP000717.1	N.A.
<i>Streptococcus pneumoniae</i>	1313	% Ident.	80.0%	N.A.	N.A.	N.A.	72.7%	N.A.
		Acc. No.	CP007593.1	N.A.	N.A.	N.A.	CP001845.1	N.A.
<i>Streptococcus pyogenes</i>	1314	% Ident.	N.A.	N.A.	N.A.	N.A.	81.8%	N.A.
		Acc. No.	N.A.	N.A.	N.A.	N.A.	AE009949.1	N.A.
<i>Bordetella pertussis</i>	520	% Ident.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
		Acc. No.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
<i>Mycoplasma pneumoniae</i>	2104	% Ident.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
		Acc. No.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
<i>Pneumocystis jirovecii</i>	42068	% Ident.	50.0%	N.A.	66.7%	54.2%	N.A.	78.3%
		Acc. No.	AY685194.1	N.A.	AY127566.1	AY130996.1	N.A.	JX499143.1
<i>Candida albicans</i>	5476	% Ident.	60.0%	N.A.	59.3%	N.A.	N.A.	65.2%
		Acc. No.	NC_002653.1	N.A.	NC_002653.1	N.A.	N.A.	NC_002653.1
<i>Pseudomonas aeruginosa</i>	287	% Ident.	80.0%	66.7%	N.A.	N.A.	81.9%	N.A.
		Acc. No.	NZ_CP040684.1	NZ_CP027174.1	N.A.	N.A.	NZ_CP007147.1	N.A.
<i>Staphylococcus epidermidis</i>	1282	% Ident.	N.A.	N.A.	N.A.	66.7%	N.A.	N.A.
		Acc. No.	N.A.	N.A.	N.A.	NZ_CP018842.1	N.A.	N.A.
<i>Streptococcus salivarius</i>	1304	% Ident.	70.0%	62.9%	N.A.	62.5%	77.3%	82.6%
		Acc. No.	NZ_CP040804.1	NZ_CP018187.1	N.A.	NZ_CP018189.1	NZ_CP020451.2	NZ_CP020451.2

A number of individual primers or probes had > 80% identity. However, potential cross-reactivity was not identified in full primer/probe sets. To confirm that cross-reactivity does not occur, amplification of these pathogens with the SARS-CoV-2 assay was performed. Additionally, the common respiratory coronaviruses (strains 229E, NL63, and OC43) and DNA templates corresponding to the N gene sequence of SARS (position 29034 – 29233 and 28669 – 28868 of NC_004718.3) were tested. None of the pathogens tested by the SARS-CoV-2 RT-PCR assay generated detectable amplification signals.

Table 8: Wet testing for cross reactivity

Pathogen	Source	Concentration	SARS-CoV-2 rRT-PCR C _T	Internal Control C _T
Coronavirus 229E	Zeptomatrix	1x10 ^{4.10} TCID ₅₀ /mL	N.D. ²	29.47
Coronavirus NL63	Zeptomatrix	1x10 ^{3.75} TCID ₅₀ /mL	N.D.	30.39
Coronavirus OC43	Zeptomatrix	1x10 ^{4.10} TCID ₅₀ /mL	N.D.	28.83
SARS NC_004718	IDT	5x10 ⁴ copies/mL	N.D.	N.A. ³
Parainfluenza virus 1	Zeptomatrix	1x10 ⁴ PFU/mL	N.D.	29.56
Enterovirus	Zeptomatrix	5x10 ⁴ copies/mL	N.D.	30.07
Rhinovirus	Zeptomatrix	1x10 ⁴ PFU/mL	N.D.	29.80
<i>Haemophilus influenza</i>	Zeptomatrix	5x10 ⁴ CFU/mL	N.D.	29.61
<i>Legionella pneumophila</i>	Zeptomatrix	5x10 ⁴ CFU/mL	N.D.	29.71
<i>Mycobacterium tuberculosis</i>	ATCC	5x10 ⁴ GEq/mL	N.D.	N.A.
<i>Streptococcus pneumoniae</i>	Zeptomatrix	5x10 ⁴ CFU/mL	N.D.	32.70
<i>Streptococcus pyogenes</i>	Zeptomatrix	5x10 ⁴ CFU/mL	N.D.	29.82
<i>Pseudomonas aeruginosa</i>	Zeptomatrix	5x10 ⁴ CFU/mL	N.D.	29.67
<i>Streptococcus salivarius</i>	Zeptomatrix	5x10 ⁴ CFU/mL	N.D.	29.77
Pooled human nasal wash	De-identified residual	N.A. ¹	N.D.	30.57
Pooled human NP swab (UTM)	De-identified residual	N.A.	N.D.	32.17
Pooled human BAL	De-identified residual	N.A.	N.D.	32.02

¹Not applicable

²Not detected

³Obtained as a genomic DNA sample therefore extraction was not performed

5) Clinical Evaluation

Clinical evaluation of the SARS-CoV-2 RT-PCR assay was performed by spiking IVT into known negative nasopharyngeal swab samples at concentrations ranging from 2x LoD through the range of the assay*. A signal was detected for all samples at each spiking concentration. However, one sample at 2x LoD yielded a C_T of 38.2 which is above the C_T cutoff for the assay, yielding 95% (19 of 20) positive agreement at 2x LoD. An agreement of 100% was achieved for all 42 spiked nasopharyngeal swabs samples at higher concentrations. All 30 negative specimens were negative for SARS-CoV-2 and each had an internal control C_T value <35.

*The clinical study was conducted in March 2020 and initially published at the time of the original authorization of the prescription use only Viracor SARS-CoV-2 Assay on April 6, 2020, when SARS-CoV-2 virus isolates or clinical samples were not widely available.

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

Table 9: Clinical performance of the SARS-CoV-2 RT-PCR test in nasopharyngeal swab

Fold of LoD	RNA concentration (copies/mL)	No. pos./ No. tested	Agreement	SARS-CoV-2 Mean C _T (SD) ²	Internal Control Mean C _T (SD)
Negative	N.A. ¹	30/30	100%	N.D. ³	31.15 (1.06)
2x	146	19/20	95%	34.92 (0.71)	N.A.
8x	585	6/6	100%	32.75 (0.35)	N.A.
80x	5,850	6/6	100%	29.44 (0.33)	N.A.
800x	5.8 x 10 ⁴	9/9	100%	25.96 (0.47)	N.A.
8000x	5.8 x 10 ⁵	6/6	100%	22.77 (0.30)	N.A.
80,000x	5.8 x 10 ⁶	9/9	100%	19.26 (0.34)	N.A.
800,000x	5.8 x 10 ⁷	6/6	100%	16.03 (0.29)	N.A.

¹Not applicable

²Standard deviation

³Not detected

[It should be noted that the internal control value is displayed as N.A. because a signal was detected in the SARS-CoV-2 channel.]

In addition, the first 5 positive and first 5 negative results from patient specimens tested with this assay were sent to the Missouri Department of Health and Senior Services for confirmation testing. All 10 specimens yielded concordant results.

6) Adding population screening of individuals without symptoms or other reasons to suspect COVID-19 to an authorized test

Data was provided to support testing of a screening population consisting of individuals without symptoms or other reasons to suspect COVID-19. Testing using the Viracor SARS- CoV-2 Assay was performed using the ThermoFisher KingFisher FLEX instrument with ThermoFisher MagMAX Viral/Pathogen Nucleic Acid Isolation kits for nucleic acid extraction, and RT-PCR amplification by the Applied Biosystems 7500 Fast Real-Time PCR Systems (SDS v1.5.1) with TaqPath 1-step RT-qPCR master mix CG kits for nucleic acid amplification and detection. The comparator was a highly sensitive FDA EUA authorized assay.

Samples were collected from individuals not exhibiting clinical signs characteristic of SARS-CoV-2 infection (i.e. individuals being screened) or other reasons to suspect COVID-19. The samples tested were anterior nasal swab specimens collected during community screening events with initial testing by Viracor Eurofins Clinical Diagnostic Laboratories. A total of 511 samples were tested with the Viracor SARS-CoV-2 Assay. Of these 23 consecutively collected positive specimens and 102 consecutively collected negative specimens were also tested with the comparator assay. All samples were stored at -70°C (or colder) after collection, and all samples were fully de-identified prior to re-testing with the comparator assay. A summary of results is shown in the table below.

Table 10: Results of Clinical Evaluation Individuals Without Symptoms or Other Reasons to Suspect COVID-19

		FDA EUA Authorized Assay		Total
		Positive	Negative	
Viracor SARS CoV-2 Assay	Positive	19	4	23
	Negative	0	102	102*
	Total	19	106	125

*102 of 488, subjects with negative Viracor SARS CoV-2 Assay results were consecutively collected and were tested by the comparator FDA EUA Authorized assay.

Because all negative samples were not tested by the comparator assay, there is verification bias. To address this, the clinical evaluation data was adjusted and then used to calculate performance estimates. Tables with the adjusted clinical data and performance estimates are provided below:

Table 11: Adjusted Results of Clinical Evaluation Individuals Without Symptoms or Other Reasons to Suspect COVID-19

		FDA EUA Authorized Assay		Total
		Positive	Negative	
Viracor SARS CoV-2 Assay	Positive	19	4	23
	Negative	0	488	488
	Total	19	492	513

Table 12: Performance Estimates of Clinical Evaluation Individuals Without Symptoms or Other Reasons to Suspect COVID-19

	Estimate	95%CI
Positive Percent Agreement (PPA)	100% (19/19)	(51.5%; 100%)*
Negative Percent Agreement (NPA)	99.2% (488/492)	(97.9%; 99.7%)*
Positive Predictive Value (PPV)	82.6% (19/23)	(62.9%; 93.0%)
Negative Predictive Value (NPV)	100% (102/102)	(96.4%; 100%)

*95%CI for PPA and NPA were adjusted to account for the fact that only 102 out of 488 samples negative by Viracor-SARS-CoV-2 Assay were tested by the comparator assay.

8) Home Collection Validation

Shipping Stability for the EmpowerDx At-Home COVID-19 PCR Kit:

Summer Profile

The EmpowerDX At-Home COVID-19 PCR Test Kit uses wrapped polyester anterior nasal swabs transported in 0.9% saline and therefore references the COVID-19 swab summer profile stability studies conducted by Quantigen Biosciences through the right of reference granted to any sponsor wishing to pursue an EUA request.

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

Two SARS-CoV-2-positive pools (2xLoD and 10xLoD) were contrived by combining SARS- CoV-2- negative human/porcine matrix with previously confirmed, high-positive patient samples. The 2xLoD and 10xLoD pools were added directly to swabs through a procedure that mimics an anterior nasal swabbing action: swabs were submerged into a reservoir of either 2xLoD or 10xLoD mixture and “abraded” against the side of the (Eppendorf style) tube while the viral solution absorbs into the swab (whether foam or polyester). The 20 low-positive samples and the 10 intermediate-positive samples used with each test condition did not come from individual patients. Rather, for each of the two concentrations, a single preparation of virus + media or virus + matrix was prepared, from which technical replicates were prepared.

The human/porcine negative matrix swabs were prepared by spiking them into negative porcine nasal mucous using the same procedure described above. Swabs were then placed into 1 mL saline.

Samples were tested using an EUA authorized assay at times 0, 30 hours, and 54 hours post incubation. Samples were held at 40°C for 12 hours, then 32°C for 18 or 42 hours, respectively. Samples were equilibrated to room temperature for 2 hours before testing.

The acceptance criteria laid out for the study was a 95% agreement or greater for positive samples. Both time points met this criteria and supported sample shipping stability, using a drop box, with over-night or 48-hour shipping.

Table 13: Average CT values for each time point for both sample dilutions

Swab	Time point	N	Internal Control	Target 1	Target 2	Target 3
2xLoD swab in saline	0 h	5	23.74	32.23	30.03	31.80
10xLoD swab in saline	0 h	5	23.27	29.46	27.58	28.67
2xLoD swab in saline	30 h	20	26.00	32.69	31.33	34.59
10xLoD swab in saline	30 h	10	26.19	29.54	28.37	28.69
2xLoD swab in saline	54 h	20	25.70	32.03	31.09	32.10
10xLoD swab in saline	54 h	10	26.11	28.73	27.25	25.09

Winter Profile

Table 14. Winter temperature stability assessment conditions

Cycle period	Temperature	Cycle period time (hrs)	Elapsed time (hrs)
1	-10°C	8	8
2	18°C	4	12
3	-10°C	2	14
4	10°C	36	50
5	-10°C	6	56

For this study, contrived samples were prepared by spiking an inactivated, residual, de-identified SARS-CoV-2 positive clinical sample at concentrations of 2xLOD and 8xLOD into nasal swab matrix collected with the EmpowerDx nasal swab kit by healthy volunteers. Twenty samples at 2xLOD, 10 samples at 8xLOD, and 10 negative (un-spiked) samples were prepared for this study and subjected to the sequential time and temperature variations shown above. Matched time 0 controls (negative, 2xLOD, and 8xLOD) were prepared simultaneously and tested using the Viracor SARS-CoV-2 EUA authorized RT-PCR assay immediately following preparation. Following the final cycle (-10°C, 6 hr), samples were allowed to equilibrate to room temperature before testing with the Viracor SARS-CoV-2 EUA authorized RT-PCR assay. Results are summarized in the table below. All un-spiked samples did not return a C_T value (i.e. “Not detected” or negative). All samples spiked at 2xLOD and 8xLOD returned a C_T value and were positive for SARS-CoV-2 (“Detected”, C_T ≤ 38).

Table 15. Control and winter temperature stability panel SARS-CoV-2 RT-PCR results

Sample set	Control (time 0)			Post-winter temperature cycling		
	No. pos/ no. tested	Mean C _T	C _T SD	No. pos/ no. tested	Mean C _T	C _T SD
Negative	0/5	N.D. ¹	N.A. ²	0/10	N.D.	N.A.
2xLOD	5/5	35.44	0.97	20/20	34.75	0.82
8xLOD	5/5	33.08	0.39	10/10	32.51	0.37

¹N.D., Not detected

²N.A., Not applicable

Agreement with expected and control results was 100% for low positive samples, 100% for high positive samples and 100% for negative samples. The mean C_T shift for low positive samples was -0.69 cycles and for high positive samples was -0.57 cycles relative to time 0 control values. These results indicate acceptable specimen stability under the evaluated simulated winter shipping conditions.

Performance criteria were met for summer and winter shipping stability studies indicating acceptable specimen stability under the evaluated simulated summer and winter shipping conditions.

Human Usability Studies for the EmpowerDX At-Home COVID-19 PCR Kit:

Human usability studies were performed with the EmpowerDX At-Home COVID-19 PCR Kit (Rx). The EmpowerDX Home Collection COVID-19 Kit DTC uses the same instructions for collecting and returning the sample as the EmpowerDX At-Home COVID-19 PCR Kit (Rx). Therefore, an additional usability study was not required.

Testing was performed with 30 participants and took place in the actual use environment (participant’s home). None of the 30 participants had medical or laboratory training or prior experience with self-collection. The ages and educational levels of the participants varied and is shown in the table below with the results of testing.

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

The entire workflow was performed by each individual participant and included registration of the kit, sample collection, packaging of the sample, and mailing to the laboratory with pre-prepared FedEx envelop. Sample collection of each participant was observed by remote visual monitoring and no difficulties were noted.

The following criteria were used to assess the sample collection procedure (a summary of results is provided after each criterion in italics):

1. Did participant read the instructions? *30 out of 30 participants indicated they had read the instructions.*
2. Did participant wash their hands before opening the kit? *30 out of 30 participants washed their hands prior to opening the kit.*
3. Did participant open the swab without touching the tip to hands/ surfaces? *30 out of 30 participants opened the swab without touching the tip to hands/surfaces.*
4. Did participant properly collect both anterior nasal swabs? *29 out of 30 participants properly collected both nostrils; one participant properly collected a single nostril.*
5. Did participant place swab in collection tube? *30 out of 30 participants placed the swab in the collection tube with the soft (collection) end contacting the liquid.*
6. Did participant spill any liquid from collection tube? *None of the 30 participants spilled any liquid from the collection tube.*
7. Did participant place vial in biohazard bag? *30 out of 30 participants placed the collection tube in the biohazard bag.*
8. Did participant place biohazard bag in the box? *30 out of 30 participants placed the biohazard bag in the box.*
9. Did participant place box in shipping envelop and seal? *30 out of 30 participants placed the box in the shipping envelop and sealed.*
10. Did any injury occur during the procedure? *None out of 30 participants experienced any injury in the procedure.*
11. Were there any deviations from the instructions? *One out of 30 participants deviated from the instructions (noted above in no. 4 in which a single nostril was collected).*

Laboratory personnel inspected the packaging and samples upon receipt. No packaging errors were noted. Each sample from the 30 participants was acceptable for testing. The following parameters were evaluated during packaging inspection (a summary of results is provided after each criterion in italics):

1. Is the sample tube in the biohazard bag? *30 out of 30 sample tubes were in a biohazard bag*
2. Is the sample tube labeled with name/barcode sticker? *29 out of 30 sample tubes were correctly labeled with the name/barcode sticker; for one sample the*

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

- barcode sticker was on the tube but did not have a name. Based on the barcode, this participant was contacted to verify the correct name of the participant.*
3. Is the DOB on the name/barcode sticker? *28 out of 30 participants correctly printed their DOB on the name/barcode sticker; for the two stickers that that did not have a DOB, follow-up contact confirmed this information.*
 4. Is the biohazard bag sealed? *30 out of 30 biohazard bags were sealed.*
 5. Is the absorbent pad in the biohazard bag? *30 out of 30 biohazard bags contained the absorbent pad.*
 6. Is a swab present in the tube? *30 out of 30 sample tubes had a swab present.*
 7. Is the volume of liquid in the tube 2 - 3 mL? *30 out of 30 sample tubes had 2 – 3 mL of liquid.*
 8. Is there evidence of leaking from the tube? *None of the 30 sample tubes showed evidence of leaking in the biohazard bag.*
 9. Is the biohazard bag with the tube in the box? *30 out of 30 biohazard bags (containing sample tubes) were in the box.*
 10. Is the consent form in the box or external package? *30 out of 30 consent forms were in the box or external packaging.*

The samples were tested for specimen adequacy using a primer/probe set that detects RNase P gene. Pre-defined acceptance criteria for sample adequacy were RNase P CT value <40 and MS2 (exogenous internal control) CT value <35. Study participants ranged in age from 19 to 58 years old and in educational level from a high school degree to a doctoral level degree. Results of testing for each of the 30 participants are shown in the following table:

Table 16: Participant age, educational level and Viracor SARS-CoV-2 Assay results

Subject ID	Age (yrs)	Education level	MS2 CT	RNase P CT
1	35	BS/BA ¹	26.80	25.35
2	56	BS/BA	26.40	26.10
3	34	MS ³	26.18	31.83
4	31	BS/BA	26.54	26.15
5	58	MS	26.40	26.65
6	55	Doctoral ⁴	26.15	31.42
7	27	Doctoral	26.30	30.55
8	55	MS	27.03	23.58
9	35	BS/BA	26.22	27.12
10	34	MS	26.36	29.25
12	46	MS	26.47	29.29
13	24	HS ⁵	26.33	29.36
14	34	MS	26.38	29.39
15	54	MS	26.74	24.37
16	50	BS/BA	26.43	31.89

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

17	57	BS/BA	26.83	25.23
18	56	BS/BA	27.17	22.56
19	22	BS/BA	26.33	27.28
20	54	Associates ⁶	26.41	27.43
21	57	BS/BA	27.16	24.17
22	30	BS/BA	26.59	25.23
23	27	Associates	26.24	28.71
24	35	BS/BA	26.67	23.52
25	31	Associates	27.46	25.30
26	21	Some college	26.23	30.71
27	48	BS/BA	26.50	25.80
28	51	BS/BA	26.54	25.22
29	22	Associates	27.31	21.03
30	19	Some college	26.28	26.48

¹4 year bachelors level degree

⁴Doctoral level degree

²Not detected (negative)

⁵High school degree

³Master’s level degree

⁶2 year associates level degree

The results from the usability indicate users 18 years of age and older are able to safely and appropriately collect an anterior nasal swab specimen with sufficient human biological material.

Limitations:

- A false negative result may occur if a specimen is improperly collected, transported or handled. False negative results may also occur if amplification inhibitors are present in the specimen or if inadequate numbers of organisms are present in the specimen.
- The performance of this test was established based on the evaluation of a limited number of clinical specimens. Clinical performance has not been established with all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.

Warnings:

- This product has not been FDA cleared or approved, but, has been authorized by FDA under an Emergency Use Authorization (EUA) for use by laboratories designated by Viracor Eurofins Clinical Diagnostics laboratory located at 1001 NW Technology Dr., Lee’s Summit, MO, that are also certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meet the requirements to perform high complexity tests.
- For in vitro diagnostic use.
- This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and

Viracor Eurofins Clinical Diagnostics Viracor SARS-CoV-2 Assay DTC
EUA Summary – January 19, 2022

- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.